Hämostaseologische Aspekte des perioperativen Blutmanagements

Zusammenfassung

Die Aktivierung der plasmatischen Gerinnungskaskade wird durch das Vorhandensein des Gewebefaktors (tissue factor, TF) auf der Oberfläche von Zellen und subendothelialen Strukturen verursacht. Die Beendigung des Gerinnungsvorganges nach z. B. Verletzungen ist ebenso überlebenswichtig wie ein schnelles Aktivieren der Gerinnungskaskade. Darüber hinaus sind physiologische Antikoagulationsmechanismen erforderlich, um dem gerinnungsaktivierenden Effekt des verlangsamten Blutstromes und des ungünstigeren Verhältnisses von Reibungsoberfläche (Endothel) und durchströmendem Blut in der Mikrozirkulation Rechnung zu tragen. Dabei handelt es sich um das Antithrombin-Glykosaminoglykan und das Thrombin- Thrombomodulin-Protein C-System. Bei einer statischen Gerinnungsstörung besteht in der Regel eine Verminderung eines einzelnen oder einer bestimmten Gruppe von Gerinnungsfaktoren oder -inhibitoren, die im zeitlichen Verlauf unverändert bleibt. Bei der dynamischen Gerinnungsstörung führt ein pathologischer prokoagulatorischer Stimulus (z. B. Trauma, Schockzustand, Endotoxin in der Sepsis, Schlangenbiss) zu einer überschießenden Aktivierung des Gerinnungssystems und damit zu einer Umsatzsteigerung der Gerinnungsfaktoren. Statische Gerinnungsstörungen können mit therapeutischer Zurückhaltung gesehen werden. Dynamische Gerinnungsstörungen können nach chirurgischer Blutstillung zuerst durch eine Inhibitorsubstitution mittels AT korrigiert werden, begleitend sollten gerinnungsaktive Frischplasmen transfundiert werden. Bei auch mit Antifibrinolytika nicht behebbaren diffusen Blutungszuständen lässt sich eine probatorische Therapie mit einem rekombinanten F VII a- Konzentrat vertreten. Zu den künftigen Perspektiven zur Verringerung des Fremdblutkomponentenverbrauchs gehören die intraoperative Gewinnung von autologem gerinnungsaktiven Frischplasma, liposomverpackte Gemische hämostaseologisch aktiver Oberflächenrezeptoren der Thrombozyten oder inhalativ applizierbare Liposome mit Thrombomodulin sowie sense- und antisense- Oligonukleotide für Gewebefaktor.

Abstract

Recent studies in humans have shown that tissue factor on the surface of endothelial cells, monocytes, or subendothelial structures sparks plasmatic coagulation. In vivo, there is no functional separation of an “endogenous” and “exogenous” pathway of the coagulation cascade. However, global laboratory tests run along such pathways due to preincubation with specific activators and, hence, allow localization of inherited coagulation defects. Coagulation inhibitors such as antithrombin or activated protein C are accelerated in their activity by cell surface glycoproteins and almost completely inactivate procoagulant activity in the microcirculation. Antithrombin binds to endothelial glycosaminoglycans and then significantly increases anticoagulant activity. Protein C is activated by the thrombin-thrombomodulin-complex and inactivates factors V a and VIII a, respectively. Additionally, activated protein C has a profibrinolytic effect. Both systems physiologically counteract the procoagulant transformation of endothelial and monocyte cell surfaces which occurs in critically ill patients due to induction of tissue factor, suppression of thrombomodulin, and removal of glycosaminoglycans from the cell surface. The distinction of statical and dynamical coagulation disorders is useful since statical disorders seldomly require therapeutic interventions although global laboratory tests may continuously deteriorate. Dynamical disorders are symptoms of an underlying disease, and consumption coagulopathy with disseminated fibrin deposition and oozing occurs when coagulation turnover cannot be stopped. Antithrombin substitution is a well documented therapeutic option along with fresh frozen plasma and erythrocyte concentrate transfusion for blood substitution. Recent case reports in patients with irreversible bleeding complications favour the application of a recombinant factor VII concentrate. A rising perspective to decrease the use of heterologous blood and blood products may be intraoperative plasma retransfusion. The quality of such plasma undergoing consecutive filtration steps has to be clinically studied. The application of a synthetic platelet substitute, the “plateletsome”, containing platelet glycoproteins led to significantly improved haemostasis without generating systemic procoagulant activity. In a far future, procoagulant cell surface transformation may be influenced by topic application of inhaled thrombomodulin loaded liposomes or by sense or antisense oligonucleotides inducing thrombomodulin expression or suppressing tissue factor expression, respectively.

Blutgerinnung - Blutung - Gerinnungsstörung - Gerinnungsfaktoren - perioperatives Management - Verbrauchskoagulopathie - Transfusion

Bleeding - coagulation - coagulation disorders - coagulation factors - perioperative blood management - transfusion

Literatur

• 1 Altieri D C, Morrissey J H, Edgington T S. Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade.  Proc Natl Acad Sci USA. 1988;  85 7462-7466
• 2 Amiral J, Bridey F, Wolf M, Boyer- Neumann C, Fressinaud E, Vissac A M, Peynaud-Debayle E, Dreyfus M, Meyer D. Antibodies to macromolecular platelet factor 4 - heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases.  Thromb Haemostas. 1995;  73 21-28
• 3 Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine.  Biochemistry. 1986;  25 4007-4020
• 4 Bernstein D. Effectiveness of the recombinant factor VII a in patients with the coagulopathy of advanced child’s B and C cirrhosis.  Semin Thromb Hemost. 2000;  26 437-438
• 5 Boldt J, Zickmann B, Ballesteros M, Oehmke S, Stertmann F, Hempelmann G. Influence of acute preoperative plasmapheresis on platelet function in cardiac surgery.  J Cardiothorac Vasc Anesth. 1993;  7 4-9
• 6 Canonico A E, Conary J T, Meyrick B O, Brigham K L. Aerosol and intravenous transfection of human alpha 1-antitrypsin gene to lungs of rabbits.  Am J Respir Cell Mol Biol. 1994;  10 24-29
• 7 Conway E M, Rosenberg R D. Tumor necrosis factor suppresses transscription of thrombomodulin gene in endothelial cells.  Mol Cell Biol. 1988;  8 5588-5592
• 8 Dahlbäck B. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.  Semin Thromb Hemost. 1999;  25 273-289
• 9 Edwards E L, Rickles F R. The role of leucocytes in the activation of blood coagulation.  Semin Hematol. 1992;  29 202-212
• 10 Ehrmann M E, Jaffe E A. Prostacyclin (PGI₂) inhibits the development in human platelets of ADP and arachidonic acid-induced shape change and procoagulant activity.  Prostaglandins. 1980;  20 1103-1109
• 11 Esmon C T, Owen W G. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C.  Proc Natl Acad Sci USA. 1981;  78 2249-2252
• 12 Fielding R M. The use of inhaled liposome formulations for drug delivery to the lungs and systemic circulation.  Proc West Pharmacol Soc. 1989;  32 103-106
• 13 Galvin J B, Kurosawa S, Moore K, Esmon C T, Esmon N L. Reconstitution of rabbit thrombomodulin into phospholipid vesicles.  J Biol Chem. 1987;  262 2199-2205
• 14 Garry B, Lisman S, Wurm W H. Intraoperative reinfusion of whole blood using a new autoinfusion device.  Can J Anaesth. 1993;  40 791-795
• 15 Gregory S A, Morrissey J H, Edgington T S. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin.  Mol Cell Biol. 1989;  9 2752-2755
• 16 Holmsen H. Biochemistry and function of platelets. Composition of platelets. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA (Hrsg). Hematology. McGraw Hill, New York 1991; 1182-1200
• 17 Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III - dependent but not thrombin-dependent prostacyclin production in human endothelial cells.  Thromb Res. 1990;  59 895-904
• 18 Howdieshell T R, Gay M, DiPiro J T, Mooney S, Duvall R, Eckles S, Baisden R. Heparin versus citrate regional anticoagulation during autotransfusion in a porcine intra-abdominal hemorrhage model.  Am Surg. 1997;  63 1014-1018
• 19 Kashima I, Ueda T, Shimizu H, Mitsumaru A, Tsutsumi K, Iino Y, Enoki C, Koizumi K, Kawada S. Efficacy of autologous platelet-rich plasma in thoracic aortic aneurysm surgery.  Jpn J Thorac Cardiovasc Surg. 2000;  48 708-712
• 20 Langer R. Drug delivery. Drugs on target.  Science. 2001;  293 58-59
• 21 Lim T K, Bloomfield V A, Nelsestuen G L. Structure of the prothrombin- and blood clotting factor X-membrane complexes.  Biochemistry. 1977;  16 4177-4181
• 22 Mann K G, Krishnaswamy S, Lawson J H. Surface-dependent hemostasis.  Semin Hematol. 1992;  29 213-226
• 23 Marcum J A, McKenney J B, Rosenberg R D. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparin-like molecules bound to the endothelium.  J Clin Invest. 1984;  74 341-345
• 24 Marcum J A, Rosenberg R D. Anticoagulantly active heparan sulfate proteoglycan and the vascular endothelium.  Semin Thromb Hemost. 1987;  13 464-474
• 25 Menges T, Welters I, Wagner R M, Boldt J, Dapper F, Hempelmann G. The influence of acute preoperative plasmapheresis on coagulation tests, fibrinolysis, blood loss and transfusion requirements in cardiac surgery.  Eur J Cardiothorac Surg. 1997;  11 557-563
• 26 Monroe D M, Hoffman M, Allen G A, Roberts H R. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia.  Semin Thromb Hemost. 2000;  26 373-377
• 27 Moore K L, Andreoli S P, Esmon N L, Esmon C T, Bang N U. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro.  J Clin Invest. 1987;  79 124-130
• 28 Mortelmans Y, Vermaut G, Van Aken H, Goossens W, Boogaerts M. Quality of washed salvaged red blood cells during total hip replacement: a comparison between the use of heparin and citrate as anticoagulants.  Anesth Analg. 1994;  79 357-363
• 29 Nakamura K, Okamoto M, Akioka K, Matsuyama M, Yoshimura R, Ushigome H, Kadotani Y, Ohmori Y, Yoshimura N. Effect of antisense oligonucleotides for tissue factor on hepatic ischemia-reperfusion injury in the rat.  Transplant Proc. 2001;  33 3707-3708
• 30 Niewiarowski S, Thomas D P. Platelet factor 4 and adenosine diphosphate release during human platelet aggregation.  Nature. 1969;  222 1269-1272
• 31 Osterud B, Rapaport S I. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation.  Proc Natl Acad Sci USA. 1977;  74 5260-5264
• 32 Ostrovsky L, Woodman R C, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion.  Circulation. 1997;  96 2302-2310
• 33 Prescott S M, Zimmermann G A, McIntyre T M. Platelet-activating factor.  J Biol Chem. 1990;  265 17 381-17 384
• 34 Rosenberg R D, Bauer K A. Thrombosis in inherited deficiencies of antithrombin, protein C, and protein S.  Hum Pathol. 1987;  18 253-262
• 35 Rybak M E, Renzulli L A. A liposome based platelet substitute, the plateletsome, with hemostatic efficacy.  Biomater Artif Cells Immobilization Biotechnol. 1993;  21 101-118
• 36 Sakata Y, Curriden S, Lawrence D, Griffin J H, Loskutoff D J. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity.  Proc Natl Acad Sci USA. 1985;  82 1121-1125
• 37 Scherer R, Kabatnik M, Erhard J, Peters J. The influence of antithrombin III substitution to supra-normal activities on systemic procoagu-lant turnover in patients with end-stage chronic liver disease.  Intensive Care Med. 1997;  23 1150-1158
• 38 Scherer R, Paar D, Stöcker L, Kox W. Diagnose und Therapie pathologischer Gerinnungsaktivierungen.  Anästhesist. 1994;  43 347-354
• 39 Scherer R, Pulletz S. Consequences of haemostasis disorders on anaesthetic management.  Current Opinion in Anesthesiology. 1999;  12 349-352
• 40 Scherer R, Schmidt U, Paar D, Kox W. Effects of prostacyclin (PGI₂) substitution on systemic procoagulant turnover and cardiorespiratory variables in experimental hypercoagulability.  Haemostasis. 1997;  27 16-24
• 41 Scherer R. Anästhesiologie - ein handlungsorientiertes Lehrbuch. Thieme Verlag Stuttgart 2000; 1. Aufl: 151-152
• 42 Stephens A C, Rivers R P. Suppression of human monocyte tissue factor synthesis by antisense oligodeoxynucleotide.  Thromb Res. 1997;  85 387-398
• 43 Stern E M, Esposito C, Gerlach H, Gerlach M, Ryan J, Handley D, Nawroth P. Endothelium and regulation of coagulation.  Diabetes Care. 1991;  14 160-166
• 44 Triulzi D J, Gilmor G D, Ness P M, Baumgartner W A, Schultheis L W. Efficacy of autologous fresh whole blood or platelet-rich plasma in adult cardiac surgery.  Transfusion. 1995;  35 627-634
• 45 Trubetskoy V S, Torchilin V P, Kennel S, Huang L. Cationic liposomes enhance targeted delivery and expression of exogenous DNA mediated by N-terminal modified poly(L-lysine)-antibody conjugate in mouse lung endothelial cells.  Biochim Biophys Acta. 1992;  1131 311-313
• 46 Uchiba M, Okajima K. Antithrombin III (AT III) prevents LPS-induced pulmonary vascular injury: novel biological activity of AT III.  Semin Thromb Hemost. 1997;  23 583-590
• 47 Van’t Veer C, Mann K G. The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VII a in refractory bleeding disorders.  Semin Thromb Hemost. 2000;  26 367-372
• 48 Vane J R, Änggard E E, Botting R M. Regulatory functions of the vascular endothelium.  N Engl J Med. 1990;  323 27-36
• 49 Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development.  Drugs. 1995;  49 856-884
• 50 Walker F J, Fay P J. Regulation of blood coagulation by the protein C system.  FASEB J. 1992;  6 2561-2567
• 51 Weiss H J, Turitto V T. Prostacyclin (prostaglandin I₂, PGI₂) inhibits platelet adhesion and thrombus formation on subendothelium.  Blood. 1979;  53 244-249
• 52 Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells.  Biochem Biophys Res Commun. 1989;  163 1404-1411
• 53 Zur M, Nemerson Y. Kinetics of factor IX activation via the extrinsic pathway. Dependence of Km on tissue factor.  J Biol Chem. 1980;  255 5703-5707